Memantine, a noncompetitive NMDA receptor antagonist, attenuates glutamate-induced excitotoxicity by non-competitively blocking overactivated receptors, thereby protecting neurons from calcium overload and providing modest preservation of daily functioning in moderate-to-severe AD, but similarly fails to modulate tau pathology or proteostatic mechanisms [80]. The gene discussed is MAPT; the disease is Alzheimer disease.